Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma

Not yet recruiting

• Conditions: Lymphoma

• Registration Number: NCT06737835
• Lead Sponsor: Assiut University

Brief Summary

1. To assess staging accuracy of F-18 FDG PET/CT in lymphoma

2. Determine the role of F-18 FDG PET/CT in monitoring treatment response and detecting relapse or residual disease in lymphoma

3. To evaluate FDG uptake correlation with histopathological subtypes and immunophenotypes as a prognostic factor.

Detailed Description

The incidence of lymphoma in Egypt has been increasing in recent years, with a noticeable rise in both Hodgkin's and non-Hodgkin's lymphoma cases. This increase is due to better healthcare, awareness, and diagnostic advancements. Risk factors include infections, lifestyle, genetics, and immune system issues.

Lymphoma is now the fourth most prevalent cancer among Egyptian adults, accounting for approximately 8.4% of all new cancer cases annually. As the burden of lymphoma grows, it becomes essential to develop effective strategies for its diagnosis and management.

Flurodeoxyglucose F-18 (F-18 FDG) is a radiolabeled glucose analog that accumulates in metabolically active cells, such as lymphoma cells, making F-18 FDG positron emission tomography / computed tomography scan (PET/CT) highly sensitive for detecting malignant lesions. It plays a key role in staging lymphoma by assessing the extent of disease spread.

Additionally, F-18 FDG PET/CT is essential for assessing treatment response, detecting relapses early, and evaluating the prognosis of patients, offering prognostic value by evaluating residual disease and predicting recurrence. Its ability to monitor disease progression and detect recurrent lymphoma provides critical insights that guide therapeutic decisions and long-term outcomes.

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-01
• Study First Submitted QC: 2024-12-12
• Last Update Submitted: 2024-12-12
• Study First Posted: 2024-12-17
• Last Update Posted: 2024-12-17
• Study Start: 2025-01-01
• Primary Completion: 2026-12-31
• Study Completion: 2027-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

• Age: Patient must be older than 18 years.
• Confirmed Diagnosis of Lymphoma: Patient must have a confirmed diagnosis of lymphoma based on histopathology and immunophenotyping.

Exclusion Criteria

• Patients with Known concomitant malignancy.
• Pregnancy: Pregnant women due to the potential risks associated with radiation exposure from the PET/CT scan.
• Severe Renal or Hepatic Impairment: Patients with significant renal or hepatic dysfunction that could affect FDG metabolism or excretion.
• Uncontrolled Diabetes: Patients with uncontrolled diabetes (blood glucose >200 mg/dL), as it can affect FDG uptake and PET/CT results.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
primary	3 years	Treatment Response Using Deauville Score for FDG Uptake Evaluation: Evaluate FDG uptake using the 5-point scale: 1. No uptake above background; 2. Uptake ≤ mediastinum; 3. Uptake \> mediastinum but ≤ liver; 4. Moderately increased compared to liver; 5. Markedly increased compared to liver X: New uptake, unlikely related to lymphoma

Secondary Outcome Measures

Name	Time	Method
secondary	3 years	Detect early relapse or residual disease using F-18 FDG PET/CT using SUVmax, maximum standardized uptake value(g/mL )

Trial Locations

Locations (1)

Nuclear medicine- Assiut University Hospital; 🇪🇬 Assiut, Egypt